AHC Products, Inc. was cited for manufacturing-rule violations and unapproved animal drugs, including AniPrin and Rot-B-Gone.
What happened
FDA inspected AHC Products' Winchester, KY drug manufacturing facility from October 20 to 23, 2025, and reviewed the firm's November 13, 2025 response to the Form FDA 483. FDA found failures in finished-product release testing, component identity testing, process and equipment validation, and stability testing, plus marketing of unapproved new animal drugs.
What FDA found
AHC released drug lots, including a wound dressing, without finished-product laboratory testing for identity and strength, and listed microbe and heavy-metal results on Certificates of Analysis without doing those tests.
21 CFR 211.165(a)AHC did not perform identity testing on incoming active or inactive ingredients for its wound dressing.
21 CFR 211.84(d)AHC released wound-dressing lots without qualifying equipment or validating the commercial manufacturing process.
21 CFR 211.100(a)AHC did not establish or follow stability testing and expiration dating, including distributing wound dressing without an expiration date and missing stability time points for AniPrin lots.
21 CFR 211.166(a)AHC marketed AniPrin P, Rot-B-Gone, and a redacted product as animal drugs without FDA approval and with claims of treating or preventing disease.
FD&C Act sections 512(a), 501(a)(5), and 301(a)
What FDA wants
FDA asks AHC to provide independent assessments and corrective action plans for its laboratory, component/supplier, process-equipment validation, and stability programs, including testing retained or distributed batches and assessing risks to animals. FDA also tells the firm to address the unapproved new animal drug marketing; the provided letter excerpt does not state a response deadline.
Who should pay attention
- veterinary drug brands using contract manufacturers
- animal-health distributors selling aspirin or wound-care products
- quality teams responsible for supplier qualification and stability programs
This is a summary. Read the original letter on fda.gov.